Summit Therapeutics (SMMT) Profit After Tax (2017 - 2026)
Summit Therapeutics' (SMMT) quarterly Profit After Tax came in at -$215.7 million in Q2 2026, up 61.88% YoY from -$133.3 million in Q2 2025, and down 13.89% on a QoQ basis from -$189.4 million in Q1 2026.
Summit Therapeutics (SMMT) Profit After Tax (2017 - 2026) Analysis & Trends
Summit Therapeutics (SMMT) has 10 years of Profit After Tax data on file, last reported at -$215.7 million in Q2 2026.
- Quarterly Profit After Tax rose 61.88% year-over-year to -$215.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$856.0 million (down 14.7% YoY) and the FY2025 annual result came in at -$1.1 billion, down 387.92% from the prior year.
- Profit After Tax eased to -$215.7 million in Q2 2026, from -$189.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$15.8 million in Q2 2023 to a low of -$565.9 million in Q2 2025.
- A 5-year average of -$133.4 million and a median of -$58.3 million in 2024 frame the typical range for Profit After Tax.
- Annual changes were most pronounced in 2023 — Profit After Tax plunged 2242.17% — and 2024, when it soared 91.98%.
- Tracing SMMT's Profit After Tax over 5 years: stood at -$18.2 million in 2022, then sank by 101.5% to -$36.7 million in 2023, then slumped by 66.8% to -$61.2 million in 2024, then tumbled by 257.83% to -$219.0 million in 2025, then grew by 1.49% to -$215.7 million in 2026.
- The last three Profit After Tax figures came in at -$215.7 million (Q2 2026), -$189.4 million (Q1 2026), and -$219.0 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Summit Therapeutics | 10.59 Bn | 9.90 Bn | - | -215.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -215.73 Mn |
| Mar 31, 2026 | -189.42 Mn |
| Dec 31, 2025 | -219.00 Mn |
| Sep 30, 2025 | -231.79 Mn |
| Jun 30, 2025 | -565.90 Mn |
| Mar 31, 2025 | -62.91 Mn |
| Dec 31, 2024 | -61.20 Mn |
| Sep 30, 2024 | -56.25 Mn |
| Jun 30, 2024 | -60.39 Mn |
| Mar 31, 2024 | -43.47 Mn |
| Dec 31, 2023 | -36.69 Mn |
| Sep 30, 2023 | -21.27 Mn |
| Jun 30, 2023 | -15.76 Mn |
| Mar 31, 2023 | -542.38 Mn |
| Dec 31, 2022 | -18.21 Mn |
| Sep 30, 2022 | -21.43 Mn |
| Jun 30, 2022 | -16.77 Mn |
| Mar 31, 2022 | -23.16 Mn |
| Dec 31, 2021 | -27.10 Mn |
| Sep 30, 2021 | -20.46 Mn |